▲ Peaking
Business
This Blood Test Screens for Cancer. Should You Vote for It?
Multi-cancer early detection blood tests face scrutiny as regulatory milestones intersect with warnings over data and population-wide harm.
Galleri
5 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Health
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
Grail faces lingering reimbursement hurdles despite approaching a landmark FDA approval for its Galleri cancer blood test.
◼ Archived
Health
This Stock, Up Almost 70%, May Have Found Cancer's Holy 'Grail'
A multi-cancer early detection blood test draws investor enthusiasm and trial data coverage across major financial and health outlets.
◼ Archived
Business
Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote
FDA advisers are set to vote on Grail’s Galleri blood test, a potential breakthrough in early detection of multiple cancers.
◼ Archived
Business
Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
Grail stock surges over 30 percent as the FDA reviews its multi-cancer early detection blood test.